# David Pyott

> David Pyott is a Series A investor at International Council of Ophthalmology backing Medical. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [International Council of Ophthalmology](https://shizune.co/investors/profile/international-council-of-ophthalmology)
- Location: Orange, United States
- Total investments: 4
- Last investment: Aug 2017
- Lead investor: 25%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/davidpyott

David Pyott is a Series A investor at International Council of Ophthalmology in Orange focused on Medical and Biotechnology. Former Chairman and CEO of Allergan; Lead Director of Avery Dennison Corporation, member of the Supervisory Board of Royal Philips in the Netherlands, Vice Chairman of the Board of Trustees of Chapman University, member of the Governing Board of the London Business School, President of the International Council of Ophthalmology Foundation, memberof the Advisory Board of the Foundation of the American Academy of Ophthalmology, and member of BioMarin Pharmaceuticals Board of Directors.

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $1.4M–$13M |
| Series B | $6.4M–$40M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 3 | 75% |
| Biotechnology | 3 | 75% |
| Medical Device | 3 | 75% |
| Health Care | 2 | 50% |
| Biopharma | 1 | 25% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 50% |
| Series B | 2 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 75% |
| The Netherlands | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Mellon Medical | Mellon Medical provides suturing tools for surgeons to improve medical procedures. The company's goal is to help medical specialists improve patient outcomes by providing them with the best possible suturing tools. It commercializes surgical instruments to allow single-handed stitching, enabling efficient and effective suturing of tubular andlayered structures.Mellon Medical was established in 2013 and is headquartered in Nijmegen, Gelderland. | $6.4M | Series B | Aug 30, 2017 |  |
| Sienna Biopharmaceuticals | Sienna Biopharmaceuticals (“sienna”) is a company focused on the discovery, clinical development and commercialization of products in aesthetics and dermatology based on scientific breakthroughs that dramatically improve patient outcomes and physicians’ practice of medicine. | $40M | Series B | Apr 24, 2017 |  |
| Bioniz Therapeutics | Bioniz is an emerging biotechnology/drug development company focused on discovering small peptides and molecules for the treatment of autoimmune diseases and some forms of cancer. Bioniz mission is to complete proof of concept and preclinical studies of its lead technology and seek partners to conduct clinical trials for regulatory approvaland commercialization.At Bioniz, they are committed to the discovery of novel molecules that enhance the lives of people across the globe. They perform our research with integrity and conscious, and bear in mind always our responsibility to the public health and their investors.It was founded in 2009 and headquartered in Irvine, California. | $13M | Series A | Aug 01, 2016 |  |
| Zerigo Health | Clarify Medical is innovating a well-established treatment, UVB therapy, to become easier, more convenient, more empowering, and more connected for psoriasis, eczema and vitiligo patients. The company also focused on developing innovative technology, products, and services that improve care for people with chronic skin conditions.Clarify Medicalindicated for the localized phototherapeutic treatment of dermatologic conditions such as psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis, and leukoderma on all skin types (I-VI). It is the first and only connected phototherapy system that uses an app on the patient’s own smartphone (iOS or Android) to manage the dose, frequency, and duration of UVB light therapy, helping to ensure that patients receive the proper doses recommended by the American Academy of Dermatology and Vitiligo Working Group. The treatment regimen is prescribed by the patient’s physician but monitored and controlled by the Clarify System, enabling patients to administer treatment with clinical precision in the convenience of their homes. The connected system monitors dosing, adherence, compliance, patient progress, and satisfaction. | $1.4M | Series A | Dec 03, 2015 |  |

4 of 4 investments shown.

## Co-investors
- [Altitude Life Science Ventures](https://shizune.co/investors/profile/altitude-life-science-ventures) — VC Fund, 1 deal together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 1 deal together
- [BioGeneration Ventures](https://shizune.co/investors/profile/biogeneration-ventures) — VC Fund, 1 deal together
- [BOM](https://shizune.co/investors/profile/brabantse-ontwikkelings-maatschappij-bom) — VC Fund, 1 deal together
- [Clough Capital Partners](https://shizune.co/investors/profile/clough-capital-partners) — VC Fund, 1 deal together
- [Fidelity](https://shizune.co/investors/profile/fidelity-management-and-research-company) — VC Fund, 1 deal together

## About International Council of Ophthalmology

VC Fund · San Francisco, United States

The ICO works with our partners to preserve and restore vision for people around the world.

1 contacts available at International Council of Ophthalmology.

| Name | Title | Profile |
| --- | --- | --- |
| David Pyott | President | https://shizune.co/investors/profile/david-e-i-pyott |

## Similar investors

### Similar industry
- [Innova Memphis](https://shizune.co/investors/profile/innova-memphis) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## Featured in investor lists
- [Medical Device Angel Investors](https://shizune.co/investors/medical-device-angel-investors)
- [Medical Device Angel Investors in United States](https://shizune.co/investors/medical-device-angel-investors-united-states)

## FAQ

### What does David Pyott invest in?

David Pyott invests primarily in Medical, Biotechnology and Medical Device startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is David Pyott's check size?

David Pyott typically joins rounds of $1.4M–$13M at Series A and $6.4M–$40M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds David Pyott participates in.

### When did David Pyott last invest?

The most recent investment recorded for David Pyott closed in Aug 2017. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co